WGS GeneDx Holdings
- 21.350
- -2.030-8.68%
GeneDx Holdings News
GeneDx Shares Are Trading Higher After the Company on Tuesday Reported Better-than-expected Q1 Financial Results.
GeneDx Shares Are Trading Higher After the Company on Tuesday Reported Better-than-expected Q1 Financial Results.
Analysts Are Upgrading GeneDx Holdings Corp. (NASDAQ:WGS) After Its Latest Results
GeneDx Holdings Corp. (NASDAQ:WGS) just released its quarterly report and things are looking bullish. The results were impressive, with revenues of US$62m exceeding analyst forecasts by 26%, and
GeneDx Holdings First Quarter 2024 Earnings: Beats Expectations
Sector Update: Health Care Stocks Mixed Late Afternoon
Health care stocks were mixed late Tuesday afternoon with the NYSE Health Care Index adding 0.2% and the Health Care Select Sector SPDR Fund (XLV) little changed, erasing earlier gains. The iShares Bi
Top Midday Gainers
Cyclacel Pharmaceuticals (CYCC) shares surged more than 47% after the company unveiled Tuesday a private placement of about 5 million shares and warrants, targeting gross proceeds of about $8 million.
BKKT, CETX and SWVL Among Mid-day Movers
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of H&E Equipment Services, Inc. (NASDAQ:HEES) fell sharply during Tuesday's session following mixed first-quarter results.H&E Equipment posted GAAP earnings of 71 cents per share, versus market
GeneDx Holdings Is Maintained at Buy by TD Cowen
GeneDx Holdings Is Maintained at Buy by TD Cowen
TD Cowen Adjusts GeneDx Holdings' Price Target to $24 From $14, Keeps Buy Rating
TD Cowen Adjusts GeneDx Holdings' Price Target to $24 From $14, Keeps Buy Rating.
TD Cowen: Maintains GeneDx Hldgs (WGS.US) rating, adjusted from buy to buy rating, and adjusted target price from $14.00 to $24.00.
TD Cowen: Maintains GeneDx Hldgs (WGS.US) rating, adjusted from buy to buy rating, and adjusted target price from $14.00 to $24.00.
Eli Lilly Increases FY24 Outlook, Joins Brinker International, Zebra Technologies, 3M And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 100 points on Tuesday.Shares of Eli Lilly and Company (NYSE:LLY) rose sharply during Tuesday's session after the company raised its FY24 r
GeneDx Holdings Stock Gains 33% On Quarterly Results
Annovis Bio, Cyclacel Pharmaceuticals, Biodexa Pharmaceuticals Among Healthcare Movers
GeneDx Rallies After Boosting '24 Revenue View
By Rob Curran GeneDx Holdings rallied after the genetic-testing firm boosted its 2024 revenue projections late Monday. The testing firm said it was raising 2024 revenue guidance to between $235 mill
Why GeneDx Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
Shares of GeneDx Holdings Corp. (NASDAQ:WGS) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and raised its FY2024 sales guid
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersCyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shar
BTIG Maintains Buy on GeneDx Hldgs, Raises Price Target to $19
BTIG analyst Mark Massaro maintains GeneDx Hldgs (NASDAQ:WGS) with a Buy and raises the price target from $15 to $19.
GeneDx Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/30/2024 39.71% BTIG $15 → $19 Maintains Buy 04/22/2024 10.29% BTIG $11 → $15 Maintains Buy 04/15/2024 -
Q1 2024 GeneDx Holdings Corp Earnings Call
GeneDx Holdings (WGS) Receives a Buy From BTIG
Analysis
Price Target
No Data
